About this event

  • Date and time Mon 14 Feb 2022 from 6:30pm to 7:45pm
  • Location Online
  • Organised by Public Engagement Programme, The London Clinic

Join the 2022 London Clinic lecture and hear Professor Ranjit Manchanda, Professor of Gynaecological Oncology and Consultant Gynaecological Oncologist, Wolfson Institute of Population Health, Queen Mary University of London and Barts Health NHS Trust, UK, give an enthralling presentation on how preventive population genomics offers the prospect of tailoring care and interventions to those at greatest risk in society.

Preventive population genomics enables population stratification for targeting effective screening and cancer prevention strategies. Up to 10% of women’s cancers in the ovary, breast, endometrium, and bowel are caused by mutations in high-risk cancer susceptibility genes (CSGs), and are potentially preventable.

In this lecture Professor Manchanda will begin by explaining the current method to identify people with inheritable CSG mutations and how this approach has been associated with restricted access and awareness and misses over half the CSG carriers.

He will then examine how the BRCA model provides 30 years of insight and experience of how to conceive and construct care and serves as an initial model for preventive population genomics. Advances in technology and bioinformatics has made population testing technically feasible. Large scale testing of populations for cancer genes is technically feasible, acceptable and potentially cost-effective. This can identify thousands more mutation carriers to improve cancer outcomes.

Finally, Professor Manchanda will explore current populations where population-based BRCA testing is beginning to be implemented and the impacts on these populations. And he will highlight the huge potential for using both genetic and non-genetic information in complex risk prediction algorithms to stratify populations for risk adapted screening and prevention.

Join in the conversation online #RSMLive
Follow us on Twitter @RoySocMed, @ProfManchanda

Key speakers

Professor Ranjit Manchanda

Professor of Gynaecological Oncology and Consultant Gynaecological Oncologist, Wolfson Institute of Population Health, Queen Mary University of London &
Barts Health NHS Trust, UK

Speaker's biography

Ranjit Manchanda is a Professor at Wolfson Institute of Population Health (WIPH), Queen Mary University of London (QMUL); Consultant Gynaecological Oncologist at Barts Health NHS Trust, London; and Honorary Professor Department of Health Services Research, London School of Hygiene & Tropical Medicine.


His research interests are focused around Targeted Precision Prevention. This includes population-based germline testing, mainstreaming genetic testing and precision medicine approaches for risk prediction, stratification, and targeted screening & cancer prevention. He has a keen research interest in health economic issues related to these areas. He is Principal Investigator on the PROTECTOR trial, PROMISE Pilot study, GCaPPS trial, RRESDO, SIGNPOST, DETECT and UKCOGS studies.

He was awarded an NHS Innovation Accelerator (NIA) Fellowship for Population Genetic Testing (2019). He is a recipient of the RCOG Blair Bell award (2018); Dr Shyam Agarwal Memorial Oration award (2019); Helen Harris Memorial Trust travelling Fellowship; NIHR Clinical Lecturer Fellowship and ICMR Fellowship awards.

He co-Leads the Cancer Prevention Unit and is Director Graduate Studies at WIPH, QMUL. He is the Specialty Research Lead for Gynaecological Cancer, NIHR North Thames CRN. He leads the high-risk women’s Precision Prevention Clinic at Barts Health and chairs the London Cancer High risk Gynaecological Cancer MDT.


He is the Integrated Academic Training Programme Director, London Specialty School of Obstetrics & Gynaecology, Health Education England, & Lead for the RCOG Advanced Professional Module (APM) in Clinical Research for London. He is a member of number of other advisory bodies and oversight committees. He has led a number of training initiatives in Gynaecological Oncology across Europe, has served as President of the European Network of Young Gynaecological Oncologists (ENYGO) and member of the European Society of Gynaecological Oncology (ESGO) Council from 2011-2013.



View the programme

Welcome and introduction

Professor Roger Kirby, President, Royal Society of Medicine

Population genetic testing for cancer predisposition

Professor Ranjit Manchanda, Professor of Gynaecological Oncology and Consultant Gynaecological Oncologist, Wolfson Institute of Population Health, Queen Mary University of London and Barts Health NHS Trust

Vote of thanks and presentation of honorarium

Representative from the London Clinic

Close of meeting



Special rates for difficult times  

The RSM wishes to offer healthcare professionals continued learning opportunities during the coronavirus pandemic. The RSM’s weekly COVID-19 Series webinars remain free of charge, while there will be small charges to register for other online education. These fees enable the RSM to continue its programme of activities and apply during the course of the pandemic. 

Registration for this meeting will close 24 hours prior to the start time.

If UK government guidelines and restrictions change, the format of this event will be updated to comply, and all delegates will be notified via email.